Loading...
•
Mar 31, 2024
Arbutus Q1 2024 Earnings Report
Reported first quarter 2024 financial results and provided a corporate update.
Key Takeaways
Arbutus Biopharma reported a net loss of $17.9 million for the first quarter of 2024, with total revenue of $1.5 million. The company's cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2024, expected to fund operations through the second quarter of 2026.
Continued progress in advancing pipeline of HBV assets, including imdusiran and AB-101.
Initiated third Phase 2a trial combining imdusiran with an immune modulator.
Preliminary data from the single-dose portion of the AB-101-001 clinical trial showed that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects.
Expected cash runway extended through the second quarter of 2026.
Forward Guidance
Arbutus anticipates its cash reserves will be sufficient to fund operations through the second quarter of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...